



Sources of bias in observational studies of covid-19 vaccine effectiveness

Kaiser Fung MPhil, MBA¹ | Mark Jones PhD² | Peter Doshi PhD³ 

¹Numbersense, Inc., New York, New York, USA

²Institute of Evidence Based Healthcare, Bond University, Gold Coast, Queensland, Australia

³University of Maryland School of Pharmacy, Baltimore, Maryland, USA

Correspondence: Peter Doshi, PhD, University of Maryland School of Pharmacy, 220 Arch St, Floor 12, Room 01-228, Baltimore, MD, 21201, USA.

Email: pdoshi@rx.umaryland.edu

KEYWORDS

causality, covid-19, evidence-based medicine, health services research, observational studies, public health, vaccine effectiveness

1 | INTRODUCTION

In late 2020, messenger RNA (mRNA) covid-19 vaccines gained emergency authorisation on the back of clinical trials reporting vaccine efficacy of around 95%,^{1,2} kicking off mass vaccination campaigns around the world. Within 6 months, observational studies reporting vaccine effectiveness in the “real world” at above 90%, similar to trial results,^{3–6} became the trusted source of evidence upholding these campaigns. While the contemporary conversation about vaccine effectiveness has turned to waning protection, virus variants, and boosters, there has (with rare exception⁷) been surprisingly little discussion of the limitations of the methodologies of these early observational studies.

The lack of critical discussion is notable, for even highly effective vaccinations could only partially explain the drop in rates of covid-19 cases, hospitalisations, and deaths by mid-2021. For example, by March 2021, cases in the UK and United States had dropped roughly fourfold from the January peak, when the “fully vaccinated” population only reached 20% and 5%, respectively. At the same time, in Israel, cases took longer to drop despite a substantially faster vaccine rollout (Figure 1). The vaccination campaigns in these countries can thus only be part of the story.

We are aware of only one article that addresses methodological concerns in non-randomised studies of covid-19 vaccines.⁷ The author draws attention to potential biases and measurement issues, such as vaccination status misclassification, exposure differences, testing differences, attribution issues, and disease risk factor confounding. Many of these concerns are hard to confirm within specific studies due to data

unavailability (e.g., testing differences) or cannot be fixed analytically (e.g., exposure and other unmeasured quantities).

In this article, we focus on three major sources of bias for which there is sufficient data to verify their existence, and show how they could substantially affect vaccine effectiveness estimates using observational study designs—particularly retrospective studies of large population samples using administrative data wherein researchers link vaccinations and cases to demographics and medical history.

Using the information on how cases were counted in observational studies, and published datasets on the dynamics and demographic breakdown of vaccine administration and background infections, we illustrate how three factors generate residual biases in observational studies large enough to render a hypothetical inefficacious vaccine (i.e., of 0% efficacy) as 50%–70% effective. To be clear, our findings should not be taken to imply that mRNA covid-19 vaccines have zero efficacy. Rather, we use the 0% case so as to avoid the need to make any arbitrary judgements of true vaccine efficacy across various levels of granularity (different subgroups, different time periods, etc.), which is unavoidable when analysing any non-zero level of efficacy. It is also important to note that under hypothetical conditions different from the actual events of early 2021, two of these sources of bias could bias results in the opposite direction, that is, *underestimating* actual vaccine effectiveness. Finally, to draw more precise conclusions about the impact of these biases on specific published studies, we urge that all code and data available to those studies be made public.

In each of our three illustrations, we compare results based on observational study methods against randomised controlled trial

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2023 The Authors. *Journal of Evaluation in Clinical Practice* published by John Wiley & Sons Ltd.




FIGURE 1 Daily covid-19 cases and vaccination rates—United States, UK, and Israel, 2021. Israel: At 20% “fully vaccinated,” daily case rate remained high (timepoint A). At 50%, daily case rate dropped to a seasonal low (timepoint B). UK and United States: Daily case rates dropped drastically with few “fully vaccinated” (timepoint A). At 20% and 5% “fully vaccinated,” daily case rates approached seasonal lows (timepoint B). *Data source: OurWorldInData.*

(RCT) methods. For each comparison, one side represents a published study while the other is a counterfactual. In each case, we show how the gap between observational and RCT study results is due to a source of bias.

2 | CASE-COUNTING WINDOW BIAS

The pivotal covid-19 vaccine trials used a primary endpoint of lab-confirmed, symptomatic covid-19.^{8–11} Not all covid cases, however, factored into the estimate of vaccine efficacy. Investigators did not

begin counting cases until participants were at least 14 days (7 days for Pfizer) past completion of the dosing regimen, a timepoint public health officials subsequently termed “fully vaccinated.”¹² The rationale for excluding cases occurring before the start of this “case-counting window” was not provided in trial protocols—and legitimacy of excluding post-randomisation events has long been debated¹³—however, one Pfizer post-marketing document states that in the early period post-vaccination, “the vaccine has not had sufficient time to stimulate the immune system.”¹⁴

In randomised trials, applying the “fully vaccinated” case counting window to both vaccine and placebo arms is easy. But in cohort



studies, the case-counting window is only applied to the vaccinated group. Because unvaccinated people do not take placebo shots, counting 14 days after the second shot is simply inoperable. This asymmetry, in which the case-counting window nullifies cases in the vaccinated group but not in the unvaccinated group, biases estimates. As a result, a completely ineffective vaccine can appear substantially effective—48% effective in the example shown in Table 1. (The placebo data in Table 1 comes from the Pfizer Phase III randomised trial, and is the assumed case counts for the unvaccinated group in a counterfactual observational study occurring simultaneously; this setup illustrates the potential size of a case-counting window bias in a real-world setting as well as why this bias does not exist in a randomised trial.).

We are aware of just one observational study³ that addressed case-counting window bias, by using matching and designating a pseudo-study enrolment date for the unvaccinated party in each matched pair of vaccinated and unvaccinated persons. While matching mitigates case-counting window bias, this method injects an artificial and severe age bias between unvaccinated and vaccinated groups: the matched subset underrepresented patients ≥ 70 years by 50% while over-representing patients ≤ 40 years by 50%. (This occurred because the propensity to receive the vaccine is highly influenced by age. Therefore, the number of one-to-one matched pairs of elderly patients is upper bounded by the number of unvaccinated elderly while the number of one-to-one matched pairs of younger patients is upper bounded by the number of vaccinated young.).

In retrospective studies using large population samples, we propose a simple adjustment that can correct for case-counting window bias. The case rate from vaccination to the start of the case-counting window

can be observed from the vaccinated group and applied to the unvaccinated group to estimate the number of cases to be excluded before computing the relative ratio of cases. This adjustment preserves the case-counting window, while assuming the vaccine is completely ineffective before its start. Because we use the 0% efficacy assumption, this simple adjustment returns the vaccine effectiveness estimate back to zero. A similar strategy has proved useful in influenza treatment analyses.¹⁶

3 | AGE BIAS

Age is perhaps the most influential risk factor in medicine, affecting nearly every health outcome. Thus, great care must be taken in studies comparing vaccinated and unvaccinated to ensure that the groups are balanced by age. Failure to do so may lead to inaccurate estimates of vaccine effectiveness when the difference in outcomes can be explained, at least partially, by age bias.

In trials, randomisation helps ensure statistically identical age distributions in vaccinated and unvaccinated groups, so that the average vaccine efficacy estimate is unbiased, even if vaccine efficacy and/or infection rates differ across age groups (see Figure 2A).

However, unlike trials, in real life, vaccination status is not randomly assigned (see Figure 2B). While vaccination rates are high in many countries, the vaccinated remain, on average, older and less healthy than the unvaccinated because vaccines were prioritised for those older and at higher risk. Individuals also self-select for vaccination regardless of policy.

Because covid-19 related risks (of infection, disease, and complications) also vary by age, this can confound the estimate of


TABLE 1 How the asymmetric application of case counting windows can bias observational studies.

	Vaccine ^a /vaccinated	Placebo/unvaccinated
Symptomatic cases (Days 0–84) ^b	257	257
Symptomatic cases during case-counting window (Days 36–84) ^b	134	134
Participants at risk ^b	21,314	21,258
Randomised trial calculations		
Case rate with case-counting window on both arms	0.63% = 134/21314	0.63% = 134/21258
Vaccine efficacy	0% = 1 - (0.63%/0.63%)	
Observational study calculations		
Case rate applying case-counting window on vaccinated only	0.63% = 134/21314	1.21% = 257/21258
Vaccine effectiveness	48% = 1 - (0.63%/1.21%)	


^aHypothetical vaccine is assumed to have zero efficacy.

^bThe placebo case count includes cases reported up to Day 84 in Pfizer's pivotal vaccine trial. This number, and the (unequal) number of participants at risk, are taken from the actual reported trial results (see Pfizer's cumulative incidence graph, p. 30).¹⁵ The vaccine case rate is fictitious and matches the placebo rate to carry out calculations on a hypothetical vaccine with zero efficacy. We follow the standard convention of the 14-day case counting window, which translates to Day 36 (14 days following Dose 2, which is given 21 days after Dose 1).


(A) **RANDOMIZED CLINICAL TRIAL**
Age Distribution by Vaccination Status



(B) **OBSERVATIONAL STUDY**
Age Distribution by Vaccination Status



(D) **RANDOMIZED CLINICAL TRIAL**
Infection Rate



(C) **OBSERVATIONAL STUDY**
Infection Rate




FIGURE 2 Age bias. The higher propensity of older people to be vaccinated causes “real-world” vaccine effectiveness to deviate from vaccine efficacy in a randomised clinical trial. Notes: The age distribution under the hypothetical randomised clinical trial is taken from England’s population pyramid, as if the study population is representative.¹⁷ The age distribution for the observational study is as reported in Round 13 of the REACT-1 Study (mid-June to mid-July 2021). Infection rates by age group are taken from the REACT-1 Study, which was 0.68% during Round 13 when averaged across all age groups. RCT, randomised clinical trial; VE, vaccine efficacy/effectiveness.

vaccine effectiveness. To illustrate this, consider the REACT-1 study.¹⁸ This study conducts PCR testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on a random sample of England’s population once a month. In June–July 2021 (the most recent data available), SARS-CoV-2 positivity rates varied considerably by age (from 1.7 to 15.6 positives per 1000 individuals), with higher rates among people under 25 years of age (see Figure 2C).

REACT-1 also reports vaccination status. As seen in Figure 2B, almost half of the unvaccinated group is aged between 5 and 12, while the most common age group in the vaccinated was 45–54 years old. While details differ, age bias is present in all observational data sets.

To understand the impact of age bias, consider a hypothetical vaccine with zero efficacy. The vaccinated and unvaccinated groups’ case rates should be statistically identical if the vaccine were completely ineffective (Figure 2D). But age bias in observational data alters the age-weighted case rates in both the vaccinated and the unvaccinated groups, resulting in different infection rates by vaccination status. Since older people recorded lower infection rates, the age-weighted case rate of the (older) vaccinated group registered at 5.5 per 1000 while the corresponding value for the (younger) unvaccinated group was 11.2 per 1000 (Figure 2C). The resultant vaccine effectiveness, which is the relative ratio of these case rates,

reflects the interaction between differential age distributions and the correlation of covid-19 incidence with age. The vaccine effectiveness appears as 51% even though the vaccine is completely ineffective by assumption. (Note that the direction of the age bias would reverse if older age groups had suffered higher case rates during the study period.)

A viable adjustment method for this instance of Simpson’s paradox¹⁹ induced by age bias should shift 51% back to zero. Simpson’s paradox describes the condition in which aggregated and disaggregated analyses of the same data lead to contradictory findings, a common phenomenon in real-world data. Many observational studies incorporate an age term into regression models in an attempt to correct this age bias.^{4,20,21} But it has been discovered in a meta-analysis of influenza vaccine studies that standard regression adjustments insufficiently correct for the variety and magnitude of biases.²²

4 | BACKGROUND INFECTION RATE BIAS

From December 2020, the speedy dissemination of vaccines, particularly in wealthier nations (Figure 1), coincided with a period of plunging infection rates. However, accurately determining the

contribution of vaccines to this decline is far from straightforward. Indeed, the considerable variation in case decline by country, such as the time lag observed in Israel—by far the quickest to reach 50% vaccinated relative to the UK and the United States—defies simple explanation (Figure 1, timepoint “B”). The sharp drop in infections complicates estimating vaccine effectiveness from observational data in a manner similar to age bias. The risk of virus exposure was considerably higher in January than in April. Thus exposure time was not balanced between unvaccinated and vaccinated individuals. Exposure time for the unvaccinated group was heavily weighted towards the early months of 2021 while the inverse pattern was observed in the vaccinated group. This imbalance is inescapable in the real world due to the timing of vaccination rollout.

In addition, unlike trials, individuals in “real-world” studies do not stay in a single analysis subgroup throughout the study period: each person is unvaccinated on the first day of the study until the day of vaccination (or the end of the study should the person remain unvaccinated). Instead of crudely categorising individuals as either “vaccinated” or “unvaccinated,” many observational studies split each person’s exposure time into an unvaccinated period followed by a vaccinated period if the individual got vaccinated.^{4–6} This technique is essential in contexts where the vast majority of the population becomes vaccinated, to avoid losing a comparison population. However, this procedure injects a strong bias into the analysis subgroups because the unvaccinated exposure time is heavily skewed to the early period in a study while the exposure time for vaccinated people skews towards the end of the study period.

For a hypothetical vaccine with zero efficacy, the case rates for vaccinated and unvaccinated should be equal during each week of the study period. Indeed in RCTs, changes in background infection rate do not bias estimates of vaccine efficacy because by design, vaccine and placebo arms follow a synchronised dosing schedule that ensures exposure (at-risk) time is balanced, even in the context of changing infection rates.

But background infection rate bias can cause estimates of vaccine efficacy in “real world” studies to vary widely from 0%. For example, using infection rate data from an actual observational study of Danish nursing home residents,²⁰ where infection rates rapidly declined simultaneous with vaccine rollout (from 12 per 1000 residents in December 2020, to almost 0 during the last 2 weeks of the study),²⁰ vaccine effectiveness of a hypothetically ineffective vaccine appears as 67%, an illusion chiefly created because unvaccinated people were preferentially exposed to the earlier weeks of higher background infection rates (Figure 3). We note that the direction of this bias would reverse if the background infection rate were to have steadily risen during the study period (i.e., vaccinating into a wave rather than out of one).

The Danish study was one of the first “real-world” studies to recognise this background infection rate bias. The researchers added a “calendar time” adjustment term to their Cox regression model to address this bias, which reduced their estimate of vaccine effectiveness from 96% to 64%.²⁰ However, as with age bias, we believe that regression adjustment is unlikely to sufficiently cure this type of imbalance. Because the regression equation was not published, we could not make a more definitive assessment.




FIGURE 3 Vaccinating while case rates fall—RCTs versus observational studies. Left panel: Relative sizes of vaccine and placebo arms in a randomised clinical trial. Right panel: Relative sizes of vaccinated and unvaccinated groups in a real-world study. Notes: Weekly infection rates are derived from weekly number of tests and proportion positive and total resident population extracted from figure 1A and table 1 of Moustsen-Helms et al.²⁰ Proportion vaccinated at start and end of study also came from Moustsen-Helms; vaccinations and trial enrolment are assumed to grow linearly over study period.

TABLE 2 Three biases and the data required to assess them in real-world studies.

Bias source	Unvaccinated group	Vaccinated group	Data required to adjust for bias
Case-counting window	Not applied (inoperable)	Applied	Epi curve showing cases from first dose by vaccination status
Age	Younger (and by correlation, healthier)	Older (and by correlation, less healthy)	Age distribution by vaccination status; cases by vaccination status by age group; results from matching methods (if available)
Background infection rate	Exposure time earlier in calendar year 2021	Exposure time later in calendar year 2021	Infection rate by week of study; case rate by week of study by vaccination status

5 | LESSONS LEARNED

A recent commentary discussed multiple factors that can bias estimates of covid-19 vaccine effectiveness, such as vaccination status misclassification, testing differences, and disease risk factor confounding.⁷ Our article complements these observations by providing examples based on actual data sets that quantify how case-counting window bias, age bias, and background infection rate bias can profoundly complicate the analysis of observational studies, shifting covid-19 vaccine effectiveness estimates by an absolute magnitude as high as 50% to 70%. Randomised trials aim to mitigate these biases by virtue of design features, such as randomisation, placebo controls, and blinding. But while randomised trials should offer far superior protection against these biases, premarketing trials left many important questions unstudied, such as the durability of protection, interaction with other countermeasures, and effectiveness in highest-risk and other important subpopulations. Pragmatic, placebo-controlled randomised trials might have addressed some of these limitations, but after manufacturers began unblinding their trials following the emergency use authorisation in December 2020, observational studies are all we have.

Our analysis shows that real-world conditions such as non-randomised vaccination, crossovers, and trends in background infection rates introduce strong, complex biases into these observational datasets. Our contribution is to size up three important biases, the magnitude of which surprised us and may surprise you. We conclude that “real-world” studies using methodologies popular in early 2021 overstate vaccine effectiveness. Our finding highlights how difficult it is to conduct high-quality observational studies during a pandemic.

While the current situation leaves much to be desired, several steps can be taken going forward to enhance the quality of observational studies. Greater awareness of these biases could promote more appropriate adjustments in future studies, including using quasi-experimental methods. In addition, journal editors could improve transparency and reproducibility of observational studies by requiring the disclosure of underlying data and code, as well as publishing modelling equations, tables of coefficients, and standard errors.²³ Data availability severely restricted our choice of studies to examine, and also prevented us from analysing all three biases simultaneously, among the ones we selected.

As shown in Table 2, we would have needed additional information, such as (a) cases from first dose by vaccination status; (b) age distribution by vaccination status; (c) case rates by vaccination status by age group; (d)

match rates between vaccinated and unvaccinated groups on key matching variables; (e) background infection rate by week of study; and (f) case rate by week of study by vaccination status.

In future work, we hope to analyse examples using hospitalisations or deaths as endpoints, which is possible only with broader data disclosure.

The pandemic offers a magnificent opportunity to recalibrate our expectations about both observational and randomised studies. “Real world” studies today are still published as one-off, point-in-time analyses. But much more value would come from having results posted to a website with live updates, as epidemiological and vaccination data accrue. Continuous reporting would allow researchers to demonstrate that their analytical methods not only explain what happened during the study period but also generalise beyond it.

Finally, randomised studies should not be considered irrelevant in the post-authorisation phase. An element of randomisation can be incorporated into real world vaccine distribution. Where populations are still largely unvaccinated and resources do not allow vaccinating everybody at once, designs such as the stepped-wedge cluster randomised rollout^{24,25} should be given serious consideration for their ability to ethically derive important scientific information. Any tool that eliminates some amount of real-world bias would reduce the complexity of analysing observational data.

AUTHOR CONTRIBUTIONS

Kaiser Fung and Peter Doshi came up with the idea for the paper, Kaiser Fung carried out the statistical analyses and wrote the first draft. All authors were involved in discussing the content, presentation, and editing the manuscript.

CONFLICTS OF INTEREST STATEMENT

We have the following interests to declare: Peter Doshi has received travel funds from the European Respiratory Society (2012) and Uppsala Monitoring Center (2018); grants from the FDA (through University of Maryland M-CERSI; 2020), Laura and John Arnold Foundation (2017-22), American Association of Colleges of Pharmacy (2015), Patient-Centered Outcomes Research Institute (2014-16), Cochrane Methods Innovations Fund (2016-18), and UK National Institute for Health Research (2011-14); was an unpaid IMEDS steering committee member at the Reagan-Udall Foundation for the FDA (2016-2020), and is an editor at The BMJ. KF, MJ: None.



DATA AVAILABILITY STATEMENT

Data sharing is not applicable to this article as no new data were created or analysed in this study.

ORCID

Peter Doshi  <http://orcid.org/0000-0002-7804-4113>

REFERENCES

- Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. *N Engl J Med*. 2020;383(27):2603-2615. doi:10.1056/NEJMoa2034577
- Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. *N Engl J Med*. 2021;384(5):403-416. doi:10.1056/NEJMoa2035389
- Dagan N, Barda N, Kepten E, et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. *N Engl J Med*. 2021;384(15):1412-1423. doi:10.1056/NEJMoa2101765
- Haas EJ, Angulo FJ, McLaughlin JM, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. *Lancet*. 2021;397(10287):1819-1829. doi:10.1016/S0140-6736(21)00947-8
- Thompson MG, Burgess JL, Naleway AL, et al. Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among health care personnel, first responders, and other essential and frontline workers - eight U.S. locations, December 2020-March 2021. *MMWR Morb Mortal Wkly Rep*. 2021;70(13):495-500. doi:10.15585/mmwr.mm7013e3
- Vasileiou E, Simpson CR, Shi T, et al. Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study. *Lancet*. 2021;397(10285):1646-1657. doi:10.1016/S0140-6736(21)00677-2
- Ioannidis JPA. Factors influencing estimated effectiveness of COVID-19 vaccines in non-randomised studies. *BMJ Evid Based Med*. 2022;27(6):324-329. doi:10.1136/bmjebm-2021-111901
- ModernaTX, Inc. Protocol mRNA-1273-P301, Amendment 3 [Internet]. Accessed October 5, 2020. <https://www.modernatx.com/sites/default/files/mRNA-1273-P301-Protocol.pdf>
- Pfizer. PF-07302048 (BNT162 RNA-Based COVID-19 Vaccines) Protocol C4591001 [Internet]. Accessed October 5, 2020. https://pfe-pfizercom-d8-prod.s3.amazonaws.com/2020-09/C4591001_Clinical_Protocol.pdf
- AstraZeneca. Clinical Study Protocol - Amendment 2 AZD1222-D8110C00001 [Internet]. Accessed October 5, 2020. https://s3.amazonaws.com/ctr-med-7111/D8110C00001/52bec400-80f6-4c1b-8791-0483923d0867/c8070a4e-6a9d-46f9-8c32-cece903592b9/D8110C00001_CSP-v2.pdf
- Janssen Vaccines & Prevention B.V. VAC31518 (JNJ-78436735) Clinical Protocol VAC31518COV3001 Amendment 1 [Internet]. Accessed October 5, 2020. <https://www.jnj.com/coronavirus/covid-19-phase-3-study-clinical-protocol>
- Fung K. The worst kept secret will be revealed today [Internet] Big Data, Plainly Spoken (aka Numbers Rule Your World). 2020. Accessed January 13, 2022. <https://junkcharts.typepad.com/numbersruleyourworld/2020/12/the-worst-kept-secret-will-be-revealed-today.html>
- Sackett DL, Gent M. Controversy in counting and attributing events in clinical trials. *N Engl J Med*. 1979;301(26):1410-1412. doi:10.1056/NEJM197912273012602
- Pfizer. 5.3.6 Cumulative analysis of post-authorization adverse event reports of PF-07302048 (BNT162b2) received through 28-Feb-[Internet]. 2021. Accessed January 13, 2022. <https://phmp.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf>
- Pfizer and BioNTech. FDA Briefing Document Pfizer-BioNTech COVID-19 Vaccine [Internet]. December, 2020. Accessed January 13, 2022. <https://www.fda.gov/media/144245/download#page=30>
- Yorifuji T, Suzuki E, Tsuda T. Oseltamivir and abnormal behaviors: true or not? *Epidemiology*. 2009;20(4):619-621. doi:10.1097/EDE.0b013e3181a3d3f6
- Park N. Population estimates for the UK, England and Wales, Scotland and Northern Ireland - Office for National Statistics [Internet]. Office for National Statistics. 2020. Accessed January 13, 2022. <https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationestimates/bulletins/annualmidyearpopulationestimates/mid2019estimates>
- Elliott P, Haw D, Wang H, et al. REACT-1 round 13 final report: exponential growth, high prevalence of SARS-CoV-2 and vaccine effectiveness associated with Delta/Delta variant in England/England during May to July 2021 [Internet]. *bioRxiv*. September 10, 2021. <http://medrxiv.org/lookup/doi/10.1101/2021.09.02.21262979>
- Bickel PJ, Hammel EA, O'Connell JW. Sex bias in graduate admissions: data from Berkeley. *Science*. 1975;187(4175):398-404. doi:10.1126/science.187.4175.398
- Moustsen-Helms IR, Emborg HD, Nielsen J, et al. Vaccine effectiveness after 1st and 2nd dose of the BNT162b2 mRNA Covid-19 vaccine in long-term care facility residents and healthcare workers - a Danish cohort study [Internet]. *medRxiv*. March 09, 2021. <http://medrxiv.org/lookup/doi/10.1101/2021.03.08.21252200>
- Menni C, Klaser K, May A, et al. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID symptom study app in the UK: a prospective observational study. *Lancet Infect Dis*. 2021;21(7):939-949. doi:10.1016/S1473-3099(21)00224-3
- Remschmidt C, Wichmann O, Harder T. Frequency and impact of confounding by indication and healthy vaccinee bias in observational studies assessing influenza vaccine effectiveness: a systematic review. *BMC Infect Dis*. 2015;15:429. doi:10.1186/s12879-015-1154-y
- Peng RD, Hicks SC. Reproducible research: a retrospective. *Annu Rev Public Health*. 2021;42:79-93. doi:10.1146/annurev-publhealth-012420-105110
- Bell KJL, Glasziou P, Stanaway F, Bossuyt P, Irwig L. Equity and evidence during vaccine rollout: stepped wedge cluster randomised trials could help. *BMJ [Internet]*. 2021;372:n435. doi:10.1136/bmj.n435
- Alqahtani M, Mallah SI, Stevenson N, Doherty S. Vaccine trials during a pandemic: potential approaches to ethical dilemmas. *Trials*. 2021;22(1):628. doi:10.1186/s13063-021-05597-8

How to cite this article: Fung K, Jones M, Doshi P. Sources of bias in observational studies of covid-19 vaccine effectiveness. *J Eval Clin Pract*. 2023;1-7. doi:10.1111/jep.13839